22-Jul-2026
Elevance Health (ELV) Gets a Buy from Bernstein
TipRanks (Wed, 22-Jul 5:51 AM ET)
US defers more than $1B in Medicaid payments to California, Minnesota
Seeking Alpha News (Wed, 22-Jul 1:27 AM ET)
Sequoia Strategy trims Sunbelt, Elevance; exits Liberty Broadband
Seeking Alpha News (Mon, 20-Jul 10:48 AM ET)
TipRanks (Mon, 20-Jul 3:50 AM ET)
Notable healthcare headlines for the week: UnitedHealth, J&J, and Intuitive Surgical in focus
Seeking Alpha News (Sun, 19-Jul 9:05 AM ET)
Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
Business Wire (Wed, 15-Jul 6:00 AM ET)
Business Wire (Mon, 6-Jul 4:30 PM ET)
Business Wire (Thu, 25-Jun 9:00 AM ET)
Business Wire (Wed, 24-Jun 3:00 PM ET)
Elevance Health Makes Clinical Review Faster, More Connected with Health OS
Business Wire (Tue, 23-Jun 8:15 AM ET)
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 45 million medical members at the end of 2025. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states in government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.
Elevance Health trades on the NYSE stock market under the symbol ELV.
As of July 22, 2026, ELV stock price declined to $389.09 with 1,082,086 million shares trading.
ELV has a beta of 0.89, meaning it tends to be less sensitive to market movements. ELV has a correlation of 0.08 to the broad based SPY ETF.
ELV has a market cap of $84.38 billion. This is considered a Large Cap stock.
Last quarter Elevance Health reported $50 billion in Revenue and $7.45 earnings per share. This beat revenue expectation by $1 billion and exceeded earnings estimates by $1.25.
In the last 3 years, ELV traded as high as $567.26 and as low as $273.71.
The top ETF exchange traded funds that ELV belongs to (by Net Assets): VTI, VOO, IVV, SPY, VTV.
ELV has outperformed the market in the last year with a return of +43.2%, while the SPY ETF gained +20.1%. In the last 3 month period, ELV beat the market returning +19.1%, while SPY returned +6.4%. However, in the most recent 2 weeks ELV has underperformed the stock market by returning -7.1%, while SPY returned 0.0%.
ELV support price is $385.21 and resistance is $401.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ELV shares will trade within this expected range on the day.